J&J is in talks to purchase Protagonist Therapeutics, the Wall Street Journal reported, citing people familiar with the matter. https://t.co/ykJVKinOA4 ...

Key TakeawaysU.S. equity markets showed resilience, with the S&P 500 and Nasdaq Composite posting slight gains by Friday's close, while Chinese markets, notably the NASDAQ Golden Dragon China Index, experienced a significant 2.6% decline, marking its steepest fall since August 27th.Johnson & Johnson (JNJ) is reportedly in advanced discussions to acquire Protagonist Therapeutics (PTGX), according to the Wall Street Journal, a development that saw Protagonist shares surge.Geopolitical tensions escalated as Ch ...

Protagonist Therapeutics (NASDAQ:PTGX), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the company. Citing people familiar with the matter, the publication noted ...

Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter. ...

The two companies are already codeveloping a treatment for ulcerative colitis. ...

Next Tuesday kicks off a heavy week for financials with JPMorgan Chase & Co., Wells Fargo & Company, and Goldman Sachs Group Inc. (The) reporting pre-market, joined by Johnson & Johnson. The financials theme continues with Bank of America Corporation and Morgan Stanley on Wednesday, alongside ASML Holding N.V. and Abbott Laboratories. Thursday is anchored by tech giant Taiwan Semiconductor Manufacturing Company Ltd. pre-market, while American Express Company leads a final wave of financials on Friday. Discl ...

In April 2025, I published my last article about Johnson & Johnson (NYSE: JNJ ), and I rated the stock as a 'Buy.' In the conclusion of my last article, I wrote:My analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small cap companies).My academic background is ...

据了解，这是自强生滑石粉诉讼持续15年来，单一原告获赔金额最高的一起判决。不过，该赔偿数额在 强生公司上诉后可能被削减。 今天(10月10日)，强生集团总部相关负责人向南都.湾财社记者表示，公司将立即对这一判决上诉，认为 该判决结果恶劣且违宪，强生重申强生婴儿爽身粉不含石棉，也不会致癌。该负责人称，公司在上诉法 院审理的每一起间皮瘤案件中都胜诉，在17起卵巢癌上诉案件中胜诉了16起。 据悉，死者梅.摩尔是美国加利福尼亚州居民，2021年因罕见癌症间皮瘤去世，享年88岁。这种疾病通 常与长期接触石棉有关。其家属同年起诉强生公司，指控其婴儿爽身粉产品含有石棉纤维，导致摩尔患 癌。 根据法庭文件，陪审团判令强生支付1600万美元补偿性赔偿金及9.5亿美元惩罚性赔偿金。对此，强生 全球诉讼事务副总裁埃里克.哈斯在声明中表示，公司计划立即提出上诉，并称这一判决"极端且违 宪"。根据法庭文件，强生目前正面临超过6.7万起诉讼，原告均声称在使用婴儿爽身粉及其他滑石粉产 品后罹患癌症。 当地时间10月7日，美国洛杉矶县法院一陪审团裁定，强生公司须向一名死于间皮瘤的女性的家属支付 9.66亿美元(约合人民币68.8亿元)赔偿金 ...

17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA (lumateperone) Phase 3 data evaluates the impact on sexual function in MDD, reinforcing potential to reset treatment expectations European Union and United Kingdom sub-group analyses of Phase 3 data evaluate efficacy of adjunctive seltorexant compared to adjunctive quetiapine XR in MDD with insomnia symptoms ...

在经济下行、成本上升、政策驱严、创新减速的当下， 当器械研发创新周期长，而资本市场趋紧时， ——增长，不再只是技术、产品、商业模式问题， 对于全球医疗科技巨头来说，以"资本操作"的方式重塑自身结构——通过"微并购"（tuck-in M&A）补齐能力，通过与私募股权（PE）合作分担风险，构建"第二条 创新曲线"——思宇MedTech在本文中结合 美敦力 （Medtronic） 和强生医疗（J&J MedTech） 的做法，剖析其增长手段，供国内的企业参考—— 资本，不是简单 的资金补给，而是一种战略工具，一种新的创新方式。 # 从研发增长到资本增长——巨头逻辑的转向 在医疗科技产业的发展史上，"创新"几乎等同于"研发"。 几十年来，行业巨头通过持续的内部研发积累——从新器械设计、传感技术到材料迭代——维持着稳步增长。 但进入 2020 年代，这条路径的效率正在下降。 全球研发成本持续攀升：根据 EvaluateMedTech 数据，全球前 20 家医疗器械公司研发投入平均占营收的 8%–12%，但带来的新产品销售占比却在下降。产品创新的 边际收益递减，审批周期拉长、监管要求提高、临床试验成本翻倍…… 美敦力的一 ...